Discover
ADVM
Adverum Biotechnologies, Inc.
4.36
1 x 3.63
1 x 4.79
bid
ask
+
0.00
0.00%
1 @ 09:30 AM
4.49 +0.13 (2.98%)
| Ytd | -6.64% | |
| 1y | -26.23% |
4.23
day range
4.38
52 week range
| Open | 4.24 | Prev Close | 4.36 | Low | 4.23 | High | 4.38 | Mkt Cap | N/A |
| Vol | 675.98K | Avg Vol | 0.00 | EPS | N/A | P/E | N/A | Forward P/E | -0.89 |
| Beta | 1.01 | Short Ratio | 5.53 | Inst. Own | 79.11% | Dividend | N/A | Div Yield | N/A |
| Ex Div Date | N/A | Earning | N/A | 50-d Avg | N/A | 200-d Avg | N/A | 1yr Est | 29.71 |
Earning
| Date | For | Estimate | Reported | Surprise | surprise % |
|---|---|---|---|---|---|
| 2024-11-04 | 2024-09 | -1.2 | -1.3 | -0.1 | -8.33% |
| 2024-08-12 | 2024-06 | -1.27 | -0.89 | 0.38 | 29.92% |
| 2024-05-09 | 2024-03 | -1.28 | -1.5 | -0.22 | -17.19% |
| 2024-03-18 | 2023-12 | -2.8 | -2.3 | 0.5 | 17.86% |
| 2023-11-09 | 2023-09 | -3 | -3.3 | -0.3 | -10.00% |
| 2023-08-10 | 2023-06 | -3.2 | -3.1 | 0.1 | 3.13% |
Upgrade / Downgrade
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| 2024-11-19 | HC Wainwright & Co. | Upgrade | Buy | Buy |
| 2024-11-05 | RBC Capital | Upgrade | Sector Perform | Sector Perform |
| 2024-08-14 | Truist Securities | Upgrade | Buy | Buy |
| 2024-08-13 | HC Wainwright& Co. | Upgrade | Buy | Buy |
| 2024-08-13 | RBC Capital | Upgrade | Sector Perform | Sector Perform |
| 2024-07-18 | Chardan Capital | Upgrade | Buy | Buy |
Profile
Adverum Biotechnologies, Inc., a clinical-stage company, develops gene therapy product candidates to treat ocular diseases. Its lead product candidate is ixoberogene soroparvovec (ADVM-022), a single intravitreal injection gene therapy candidate used for the treatment of patients with wet age-related macular degeneration and diabetic macular edema which is in phase 2 clinical trials. The company is developing ADVM-062 (AAV.7m8-L-opsin), a novel gene therapy product candidate for the treatment of blue cone monochromacy via a single IVT injection. Adverum Biotechnologies, Inc. has license and collaboration agreements with University of California; GenSight Biologics; Lexeo Therapeutics; and Virovek, Inc. The company was formerly known as Avalanche Biotechnologies, Inc. and changed its name to Adverum Biotechnologies, Inc. in May 2016. Adverum Biotechnologies, Inc. was incorporated in 2006 and is headquartered in Redwood City, California.
Insider Holder
| Date | Name | Relation | Quantity | Description |
|---|---|---|---|---|
| 2023-03-14 | FISCHER LAURENT D M.D. | Chief Executive Officer | 692.14K | Sale |
| 2024-07-29 | LEONARD BRADEN MICHAEL | Beneficial Owner of more than 10% of a Class of Security | 0.00 | Purchase |
| 2024-02-06 | LUPHER MARK L. JR., PH.D. | Director | 0.00 | Purchase |
| 2023-03-14 | RILEY BRIGIT | Officer | 117.44K | Sale |
| 2023-06-06 | RUBINSTEIN LINDA M. | Chief Financial Officer | 100.00K | Purchase |
| 2024-02-06 | SCOPA JAMES PAUL | Director | 103.33K | Purchase |
Institution Ownership
| Report Date | Organization | Position | Value | Percentage |
|---|---|---|---|---|
| 2024-09-29 | BML Capital Management, LLC | 2.27M | 10.75M | 10.90% |
| 2024-09-29 | TCG Crossover Management, LLC | 2.01M | 9.52M | 9.65% |
| 2024-09-29 | Franklin Resources, Inc. | 1.76M | 8.34M | 8.46% |
| 2024-09-29 | Blackrock Inc. | 1.49M | 7.07M | 7.17% |
| 2024-09-29 | VR Adviser, LLC | 1.47M | 6.95M | 7.05% |
| 2024-09-29 | Frazier Life Sciences Management, L.P. | 1.07M | 5.07M | 5.14% |
Fund Ownership
| Report Date | Organization | Position | Value | Percentage |
|---|---|---|---|---|
| 2024-07-30 | Franklin Strategic Series-Franklin Biotechnology Discove | 624.74K | 2.96M | 3.00% |
| 2024-09-29 | Vanguard Total Stock Market Index Fund | 586.25K | 2.78M | 2.82% |
| 2024-10-30 | iShares Russell 2000 ETF | 543.65K | 2.58M | 2.61% |
| 2024-09-29 | Vanguard Extended Market Index Fund | 285.80K | 1.35M | 1.37% |
| 2024-08-30 | Fidelity Small Cap Index Fund | 211.58K | 1.00M | 1.02% |
| 2024-10-30 | iShares Russell 2000 Value ETF | 192.62K | 913.00K | 0.93% |
Split
| Split | Date |
|---|---|
| 1 : 10 | 2024-03-21 |